Abstract
Cellular resistance to anthracyclines is a major limitation of their clinical use in the treatment of human tumors. Resistance to doxorubicin is described as a multifactorial phenomenon involving the overexpression of defense factors and alterations in drug-target interactions. Such changes do not account for all manifestations of drug resistance, in particular intrinsic resistance of solid tumors. Since anthracyclines can induce apoptotic cell death, an alternative promising approach to drug resistance has focused on the study of cellular response to drug-induced DNA damage, with particular reference to the relationship between cytotoxicity/antitumor efficacy and apoptotic response. The evidence that a novel disaccharide analog (MEN 10755), endowed with an improved preclinical activity over doxurubicin, was also more effective as an inducer of apoptosis provided additional insights to better understand the cellular processes that confer sensitivity to anthracyclines. Although the presence or alteration of a single apoptosis-related factor (e.g., p53, bcl-2) is not predictive of the sensitivity/resistance status, the complex interplay among DNA damage-activated pathways is likely an important determinant of tumor cell sensitivity to anthracyclines.
| Original language | English |
|---|---|
| Pages (from-to) | 31-37 |
| Number of pages | 7 |
| Journal | Current Medicinal Chemistry |
| Volume | 8 |
| Issue number | 1 |
| Publication status | Published - 2001 |
Fingerprint
ASJC Scopus subject areas
- Organic Chemistry
- Biochemistry, Genetics and Molecular Biology(all)
- Biochemistry
- Pharmacology
Cite this
Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines. / Perego, Paola; Corna, Elisabetta; De Cesare, Michelandrea; Gatti, Laura; Polizzi, Donatella; Pratesi, Graziella; Supino, Rosanna; Zunino, Franco.
In: Current Medicinal Chemistry, Vol. 8, No. 1, 2001, p. 31-37.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of apoptosis and apoptosis-related genes in cellular response and antitumor efficacy of anthracyclines
AU - Perego, Paola
AU - Corna, Elisabetta
AU - De Cesare, Michelandrea
AU - Gatti, Laura
AU - Polizzi, Donatella
AU - Pratesi, Graziella
AU - Supino, Rosanna
AU - Zunino, Franco
PY - 2001
Y1 - 2001
N2 - Cellular resistance to anthracyclines is a major limitation of their clinical use in the treatment of human tumors. Resistance to doxorubicin is described as a multifactorial phenomenon involving the overexpression of defense factors and alterations in drug-target interactions. Such changes do not account for all manifestations of drug resistance, in particular intrinsic resistance of solid tumors. Since anthracyclines can induce apoptotic cell death, an alternative promising approach to drug resistance has focused on the study of cellular response to drug-induced DNA damage, with particular reference to the relationship between cytotoxicity/antitumor efficacy and apoptotic response. The evidence that a novel disaccharide analog (MEN 10755), endowed with an improved preclinical activity over doxurubicin, was also more effective as an inducer of apoptosis provided additional insights to better understand the cellular processes that confer sensitivity to anthracyclines. Although the presence or alteration of a single apoptosis-related factor (e.g., p53, bcl-2) is not predictive of the sensitivity/resistance status, the complex interplay among DNA damage-activated pathways is likely an important determinant of tumor cell sensitivity to anthracyclines.
AB - Cellular resistance to anthracyclines is a major limitation of their clinical use in the treatment of human tumors. Resistance to doxorubicin is described as a multifactorial phenomenon involving the overexpression of defense factors and alterations in drug-target interactions. Such changes do not account for all manifestations of drug resistance, in particular intrinsic resistance of solid tumors. Since anthracyclines can induce apoptotic cell death, an alternative promising approach to drug resistance has focused on the study of cellular response to drug-induced DNA damage, with particular reference to the relationship between cytotoxicity/antitumor efficacy and apoptotic response. The evidence that a novel disaccharide analog (MEN 10755), endowed with an improved preclinical activity over doxurubicin, was also more effective as an inducer of apoptosis provided additional insights to better understand the cellular processes that confer sensitivity to anthracyclines. Although the presence or alteration of a single apoptosis-related factor (e.g., p53, bcl-2) is not predictive of the sensitivity/resistance status, the complex interplay among DNA damage-activated pathways is likely an important determinant of tumor cell sensitivity to anthracyclines.
UR - http://www.scopus.com/inward/record.url?scp=0035041124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035041124&partnerID=8YFLogxK
M3 - Article
C2 - 11172690
AN - SCOPUS:0035041124
VL - 8
SP - 31
EP - 37
JO - Current Medicinal Chemistry
JF - Current Medicinal Chemistry
SN - 0929-8673
IS - 1
ER -